Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study

Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Stéphane Dalle(Mount Sinai Hospital), Luis de la Cruz‐Merino, María del Carmen Álamo de la Gala(Hospital Universitario Virgen Macarena), Sonia Maciá(Highlight Therapeutics (Spain)), Miguel F. Sanmamed(Clinica Universidad de Navarra), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Juan Francisco Rodríguez-Moreno(Hospital Universitario HM Sanchinarro), Marisol Quintero(Highlight Therapeutics (Spain)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), H. Montaudié(Centre Hospitalier Universitaire de Nice), Elisa Funk-Brentano(Hôpital Ambroise-Paré), M.P. Lopez Criado(MD Anderson Cancer Center Madrid), Alfonso Berrocal(Hospital General Universitario De Valencia), Helena Escuin-Ordinas(University of California, Los Angeles), J. Charles(Apple (Israel)), Caroline Robert(Centre National de la Recherche Scientifique), Enrique de Miguel(Universidad de Huelva), María González Cao(Hospital Universitario Dexeus), Pablo Cerezuela‐Fuentes(Hospital Universitario Virgen de la Arrixaca), Ana Arance(Hospital Clínic de Barcelona), Eduardo Castañón Álvarez(Clinica Universidad de Navarra), S. Prey(Centre Hospitalier Universitaire de Bordeaux)

Cancer Research

June 15, 2022

Cited by 6

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|New England Journal of Medicine|2014|2k

|New England Journal of Medicine|2018|1.8k

Related Papers